NCT03965962View on ClinicalTrials.gov

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

640

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

December 22, 2020

Study Completion Date

July 1, 2021

Conditions
Rabies (Healthy Volunteers)
Interventions
BIOLOGICAL

VRVg-2

"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"

BIOLOGICAL

Purified Inactivated Rabies Vaccine

"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"

BIOLOGICAL

Human Diploid Cell Vaccine (HDCV)

"Pharmaceutical form: Powder and solvent for suspension for injection;~Route of administration: IM"

BIOLOGICAL

Rabies immune globulin (human)

"Pharmaceutical form: Solution for injection;~Route of administration: IM"

Trial Locations (2)

35000

Investigational Site Number 2500001, Rennes

38610

Investigational Site Number 2500002, Gières

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03965962 - Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults | Biotech Hunter | Biotech Hunter